Clinical Trials Browser

INDUSTRY × Neoplasms × NPI 2358 × Clear all

NCT00630110 2011-08-16

Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Phase 1/2 Completed

Neoplasms

NCT00322608 2011-01-10

Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Completed

Lymphoma, Neoplasms